Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 7Carcinoma 5Neoplasm Metastasis 3Prostatic Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Vipoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1Gastrinoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms, Male 1

Interventions

Docetaxel 3sargramostim 1radium Ra 223 dichloride 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1Prednisone 1Mycobacterium w vaccine 1Everolimus 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone Refractory Prostate Cancer × epothilone B × Clear all
NCT00407251 2010-11-05

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

British Columbia Cancer Agency

Phase 2 Completed
73 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡